4D Molecular Therapeutics - About the company
4D Molecular Therapeutics is a public company based in Emeryville (United States), founded in 2013 by . It operates as a Developer of gene therapeutics for genetic disorders. 4D Molecular Therapeutics has raised $187M in funding from Viking Global Investors. The company has 101 active competitors, including 38 funded and 23 that have exited. Its top competitors include companies like EyePoint Pharmaceuticals, Rezolute and MeiraGTx.
Company Details
4d Molecular Therapeutics researchers develop gene therapy products for severe genetic diseases involving a diverse array of target tissues, including the following areas: retina, heart, liver, brain (CNS), skeletal muscle, and lung. The company uses Directed Vector Evolution, a vector discovery platform to create customized gene delivery vehicles to deliver genes to any tissue or organ in the body.
Key Metrics
Founded Year
2013
Location
Emeryville, United States
Stage
Public
Total Funding
in 6 rounds
Latest Funding Round
Investors
Ranked
1st among
Annual Revenue
as on Dec 31, 2021
Employee Count
as on Dec 31, 2023
Similar Companies
Exit Details
Public
Legal entities associated with 4D Molecular Therapeutics
4D Molecular Therapeutics is associated with 2 legal entities given below:
Legal Entity Name | Date of incorporation | Revenue | Net Profit | Employee Count |
|---|---|---|---|---|
Mar 10, 2015 | $18M (as on Dec 31, 2021) | 803 | 239 | |
Mar 10, 2015 | - | 746 | 293 |
Get your free copy of 4D Molecular Therapeutics's company profile
4D Molecular Therapeutics's funding and investors
4D Molecular Therapeutics has raised a total funding of $187M over 6 rounds. Its first funding round was on Aug 12, 2015. Its latest funding round was a Series C round on Jun 16, 2020 for $75M. 16 investors participated in its latest round, lead by Viking Global Investors.
4D Molecular Therapeutics has 20 institutional investors including Viking Global Investors, Ridgeback Capital Management and Perceptive Advisors.
Here is the list of recent funding rounds of 4D Molecular Therapeutics:
Date of funding | Funding Amount | Round Name | Post money valuation | Revenue multiple | Investors |
|---|---|---|---|---|---|
Jun 16, 2020 | $75M | Series C | 8527704 | 8269209 | Viking Global Investors, , and |
Sep 05, 2018 | $90M | Series B | 7671854 | 4198316 | |
Sep 19, 2017 | $3M | Series A | 8392345 | 1875111 |
Access funding benchmarks and valuations. Sign up today!View details of 4D Molecular Therapeutics's funding rounds and investors
4D Molecular Therapeutics's founders and board of directors
The founders of 4D Molecular Therapeutics is . is the CEO of 4D Molecular Therapeutics. has founded 2 more companies - IGNITE Immunotherapy and Jennerex Biotherapeutics.
View details of 4D Molecular Therapeutics's Founder profiles and Board Members
4D Molecular Therapeutics's employee count trend
4D Molecular Therapeutics has 147 employees as of Dec 23. The total employee count is 5.0% more than what it was in Dec 22. Here is 4D Molecular Therapeutics's employee count trend over the years:
Uncover 4D Molecular Therapeutics's growth story! Sign up today!4D Molecular Therapeutics's Competitors and alternates
Top competitors of 4D Molecular Therapeutics include EyePoint Pharmaceuticals, Rezolute and MeiraGTx. Here is the list of Top 10 competitors of 4D Molecular Therapeutics, ranked by ÃØÃÜÑо¿Ëù score :
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Overall Rank | Company Details | Short Description | Total Funding | Investors | ÃØÃÜÑо¿Ëù Score |
|---|---|---|---|---|---|
1st | 2013, Emeryville (United States), Public | Developer of gene therapeutics for genetic disorders | $187M | Ridgeback Capital Management, Perceptive AdvisorsÌý&²¹³¾±è;Ìý | 66/100 |
2nd | EyePoint Pharmaceuticals 1987, Watertown (United States), Public | Developer of small molecule-based therapeutics for treating ophthalmic disorders | - | CRG, Ìý&²¹³¾±è;Ìý | 65/100 |
3rd | Rezolute 2012, Denver (United States), Public | Biopharmaceutical company developing therapies for metabolic & orphan diseases | - | Bay City Capital, CitadelÌý&²¹³¾±è;Ìý | 61/100 |
4th | MeiraGTx 2015, New York City (United States), Public | Developer of gene therapies for ocular and neurodegenerative diseases | - | Perceptive Advisors, OrbimedÌý&²¹³¾±è;Ìý | 58/100 |
5th | Molecular Partners 2004, Zurich (Switzerland), Public | Developer of therapeutic solutions for treating multiple diseases | $59.9M | 58/100 | |
6th | Aviceda Therapeutics 2018, Cambridge (United States), Series C | Developer of biotherapeutics for glycol-immune diseases | $255M | Omega Funds, OrbimedÌý&²¹³¾±è;Ìý | 58/100 |
7th |  Kriya Therapeutics 2012, Redwood City (United States), Series C | Developer of therapeutic solutions for the treatment of diabetes | $618M | Foresite Capital, QVT Family OfficeÌý&²¹³¾±è;Ìý | 57/100 |
8th | Epicrispr Bio 2018, San Francisco (United States), Series B | Developer of therapeutics for multiple disease | $68M | Ally Bridge Group, LDV PartnersÌý&²¹³¾±è;Ìý | 55/100 |
9th | Relmada 2007, Blue Bell (United States), Public | Developing novel drug products for the treatment of multiple disease | $13M | 55/100 | |
10th | GenSight Biologics 2011, Paris (France), Public | Developer of viral vector-based gene therapies for retinal neurodegenerative diseases | $76.6M | Abingworth, Perceptive AdvisorsÌý&²¹³¾±è;Ìý | 54/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on 4D Molecular Therapeutics's competitors? Click to see the top ones
4D Molecular Therapeutics's Investments and acquisitions
4D Molecular Therapeutics has made no investments or acquisitions yet.
Reports related to 4D Molecular Therapeutics
Here is the latest report on 4D Molecular Therapeutics's sector:
View
News related to 4D Molecular Therapeutics
Media has covered 4D Molecular Therapeutics for a total of 21 events in the last 1 year, 7 of them have been about company updates and 2 about people movement.
•
GlobeNewswire•May 01, 2025•4D Molecular Therapeutics
•
GlobeNewswire•Mar 01, 2025•4D Molecular Therapeutics
•
GlobeNewswire•Feb 09, 2025•4D Molecular Therapeutics
•
PR Newswire•Feb 05, 2025•4D Molecular Therapeutics,
•
Seeking Alpha•Jan 10, 2025•4D Molecular Therapeutics
•
GlobeNewswire•Jan 10, 2025•4D Molecular Therapeutics
•
GlobeNewswire•Dec 16, 2024•4D Molecular Therapeutics
•
GlobeNewswire•Nov 14, 2024•4D Molecular Therapeutics
•
Seeking Alpha•Nov 13, 2024•4D Molecular Therapeutics
•
4DMT's gene therapy reduced need for standard-of-care injections to treat age-associated vision lossEndPoints News•Sep 19, 2024•4D Molecular Therapeutics
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Our Lite Plan Awaits you - Its Free!
Sign up now to unlock full access to curated data
4M+ Companies- 212K+ Investors
- 580K+ Funding Rounds
- 207K+ Acquisitions
- 2.9K+ Sectors
- 57K+ Business Models
Are you a Founder ?
FAQ's about 4D Molecular Therapeutics
Explore our recently published companies
- Ayzer Sense - Singapore based, 2018 founded, Unfunded company
- Aitech Mechatronics - Singapore based, 1996 founded, Unfunded company
- Sezin Medical Imaging and Heart Center - Karatay based, 2003 founded, Unfunded company
- Kindernet - Singapore based, 1997 founded, Unfunded company
- Quarero Robotics - Switzerland based, 2021 founded, Unfunded company
- Evercomm - Singapore based, 2013 founded, Unfunded company
